SynAct Pharma AB SYNACT

LUND, SE / ACCESS Newswire / September 22, 2026 / AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced its attendance and presentations at multiple upcoming conferences in September and October 2026.comInvestors and Media Mary-Ann Chang, Cohesion Bureau E-mail: synactpharma@cohesionbureau.

LUND, SE / ACCESS Newswire / September 16, 2026 / AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced that the World Health Organization (WHO) has identified resomelagon, the company's once daily oral pro-resolution therapy, as one of six dengue therapeutic candidates with evidence supporting further clinical development.In a review to guide and accelerate clinic

LUND, SE / ACCESS Newswire / September 7, 2026 / AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced results from a post-hoc analysis of the Phase 2b ADVANCE study evaluating resomelagon in treatment-naïve patients with highly active rheumatoid arthritis ("RA"). The analysis reinforces the positive results from the earlier Phase 2b EXPAND study and provides furthe

LUND, SE / ACCESS Newswire / September 3, 2026 / AB (STO:SYNACT) ("" or the "Company") today announces that the Company's Chief Executive Officer, Jeppe Øvlesen, and the Company's CSO, Thomas Jonassen, have sold shares in the Company to enable payment of capital gain tax.Jeppe Øvlesen's sale of a total of 150,000 shares at a price of SEK 17.